All In Biotech

Drug Trial Radar · NCT01687608

Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B

A Phase 1/2 Open-Label, Single Ascending Dose Trial of a Self-Complementing Optimized Adeno-associated Virus Serotype 8 Factor IX Gene Therapy (AskBio009) in Adults With Hemophilia B

Last checked: Nov 19, 2026Latest source record: Mar 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

30

Actual

Start

Feb 11, 2013

Primary completion

Jan 17, 2030

Study completion Jan 17, 2030

Sponsor

Lead sponsor
Baxalta now part of ShireTakeda (TAK)
Sponsor type
Industry
First posted
Sep 19, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety of single ascending IV doses of a Factor IX (FIX) Gene Therapy in up to 16 Adults with Hemophilia B.

Conditions

  • Hemophilia B

Interventions

  • AskBio009Biological

    Single dose IV injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of patients experiencing treatment-related adverse events by dose groupTime frame: Infusion to Week 3 and Infusion to end of study
  2. Change from baseline in clinical laboratory evaluationsTime frame: Change from baseline at week 3 and change from baseline at the end of study

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Orthopaedic Hemophilia Treatment Center

    Los Angeles, California

  • Children's Hospital Los Angeles

    Los Angeles, California

  • University of California Davis Medical Center

    Sacramento, California

  • University of California at San Diego Medical Center

    San Diego, California

  • U of Colorado School of Medicine, Hemophilia & Thrombosis Treatment Center

    Aurora, Colorado

  • Emory University

    Atlanta, Georgia

  • Rush University Medical Center

    Chicago, Illinois

  • Children's Hospital of Boston

    Boston, Massachusetts

  • University of Minnesota, Masonic Clinical Research Unit, Clinical and Translational Science Institute

    Minneapolis, Minnesota

  • Mount Sinai Medical Center

    New York, New York

  • The Hemophilia Center, Oregon Health and Science University

    Portland, Oregon

  • Medical University of South Carolina

    Charleston, South Carolina

  • Gulf States Hemophilia and Thrombosis Center

    Houston, Texas

  • Bloodworks Northwest

    Seattle, Washington

  • BloodCenter of Wisconsin

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.